Dr. Charles Wu, a well-educated and experienced leader in the pharmaceutical field, recently served as the CEO of Gyre Therapeutics, Inc. He holds a Bachelor's degree in Polymer Chemistry from the University of Science and Technology of China, and a...
Dr. Charles Wu, a well-educated and experienced leader in the pharmaceutical field, recently served as the CEO of Gyre Therapeutics, Inc. He holds a Bachelor's degree in Polymer Chemistry from the University of Science and Technology of China, and a Doctoral degree in Chemistry from the University of Maryland, along with an MBA certificate from Tulane University. With over 30 years of experience, Dr. Wu significantly contributed to the company's direction during his tenure from October 30, 2023, until January 15, 2024. Notably, he announced his retirement for health reasons, which had no connection to any company disagreements. Dr. Wu's compensation for 2023 was notably modest at $106,152, consisting only of salary without bonuses or additional stock options, reflecting a focus on personal principles rather than maximizing earnings. He has been at the forefront of important developments in the pharmaceutical sector, focusing on chemistry and its application in drug development. His journey reflects a deep commitment to science and innovation, making him a respected figure in the industry.